Duramed (DRMD) Synthetic Estrogen Product Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Doug Bean who wrote (1056)	4/3/1999 1:55:00 PM
From: Thure Meyer	Read Replies (1) of 1837

re: Tamoxifen - 3 See following URL for current patent status of Tamoxifen as well. Apparently it expires in 8/2002. barrlabs.com " FDA Affirms Barr's 180 Day Generic Tamoxifen Exclusivity Pomona, NY, March 9, 1999 -- Barr Laboratories, Inc. (NYSE-BRL) today announced that the U.S. Food and Drug Administration has granted its Citizen Petition clarifying that the Company will have 180 days of market exclusivity for its generic version of Tamoxifen Citrate when the patent protecting the brand version expires in 2002..." There is more having to do with patent disputes. Unless I read this the wrong way, the generic market won't be available to Duramed until 2003. Nonetheless, this market fits in well with their current product line as well as the emerging demographics. Maybe 4 years is to far out for most people, but I think this company has some good prospects. Thure

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next